Uno studio per valutare l'efficacia delle iniezioni di BOTOX (tossina botulinica di tipo A) per il cambiamento della prominenza del muscolo massetere nei partecipanti adulti (MMP EU P3)
BOTOX® (tossina botulinica di tipo A) per la riduzione della prominenza dei muscoli masseteri: studio di fase 3, multicentrico, randomizzato, in doppio cieco, controllato con placebo
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a narrower and more ovoid lower face shape. Treatments are available for masseter muscle prominice (MMP), but researchers are looking for new non-surgical treatments. This study will assess adverse events and effectiveness of BOTOX in adult participants with MMP.
BOTOX is being investigated for the treatment of MMP. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is 1 in 4 chance that participants will be assigned to placebo. Around 248 adult participants with MMP will be enrolled in the study at approximately 30 sites in Europe.
Participants will receive either BOTOX or Placebo administered as 6 intramuscular injections to the masseter on Day 1. Participants who are eligible for retreatment will be given BOTOX on Day 180 and will be followed for up to 6 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Antwerpen
-
Beerse, Antwerpen, Belgio, 2340
- Da Vinci Clinic /ID# 246731
-
Schilde, Antwerpen, Belgio, 2970
- Evolve Clinic /ID# 246729
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgio, 1090
- Universitair Ziekenhuis Brussel /ID# 246311
-
-
Oost-Vlaanderen
-
Melle, Oost-Vlaanderen, Belgio, 9090
- Lightfalls Clinic /ID# 247335
-
-
-
-
-
Plovdiv, Bulgaria, 4000
- Dermavist - Group Practice for Specialized Medical Care for Skin Disease /ID# 247630
-
Sofia, Bulgaria, 1700
- Medical Centre Dermatology Dr. Denkova EOOD /ID# 246591
-
Sofia, Bulgaria, 1407
- Medical Center Derma Vita EOOD /ID# 247327
-
-
-
-
-
Antibes, Francia, 06160
- Mediti /Id# 246875
-
Cannes, Francia, 06400
- Cabinet Dermatologie et Esthetique /ID# 246871
-
Paris, Francia, 75007
- Cabinet médical /ID# 246873
-
Toulouse, Francia, 31000
- Cabinet de Chirurgie Plastique et Esthétique /ID# 246872
-
-
-
-
-
Hamburg, Germania, 20146
- Universitaet Hamburg /ID# 247503
-
-
Bavaria
-
Munich, Bavaria, Germania, 80333
- Hautok and Hautok-cosmetics /ID# 246600
-
Munich, Bavaria, Germania, 80333
- Studienzentrum Theatiner46 /ID# 246601
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Germania, 50996
- Hautzentrum Koeln /ID# 247502
-
Düsseldorf, North Rhine-Westphalia, Germania, 40212
- Privatpraxis Dr. Hilton & Partner /ID# 246602
-
-
-
-
-
Latina, Italia, 04100
- Azienda Unita Sanitaria Locale Latina /ID# 246835
-
Roma, Italia, 00128
- Fondazione Policlinico Universitario Campus Bio-Medico /ID# 246836
-
Verona, Italia, 37134
- CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 246834
-
-
-
-
-
Edinburgh, Regno Unito, EH3 6RS
- Dr Nestor's Medical Cosmetic Centre /ID# 246437
-
London, Regno Unito, W1H 6AZ
- Interface Aesthetics Training Limited /ID# 248115
-
Sutton Coldfield, Regno Unito, B74 2UG
- MediZen /ID# 246431
-
-
North Lanarkshire
-
Coatbridge, North Lanarkshire, Regno Unito, ML5 3AP
- Waverley Medical Practice /ID# 246432
-
-
-
-
-
Madrid, Spagna, 28006
- Grupo Pedro Jaen /ID# 246485
-
Madrid, Spagna, 28008
- Clinica Robega /ID# 252239
-
-
Pontevedra
-
Vigo, Pontevedra, Spagna, 36201
- Gavín Dermatólogos /ID# 252120
-
-
Valencia
-
Valencia, Valencia, Spagna, 46004
- Clinica Alejandria /ID# 247380
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Body mass index < 30 kg/m^2 using the calculation: BMI = weight (kg)/height (m)^2, rounded to the nearest whole number.
-
Participants meets the following criteria:
- Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right side of the face), as determined at screening and at the Day 1 visit by the investigator using the MMPS.
- Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right sides of the face), as determined at the Day 1 visit by the participant using the MMPS-P.
- MMP grades, as assessed by investigator and participant, do not need to be identical but have to be a minimum of Grade 4 with bilateral symmetry at Day 1.
-
Participants who responded "A lot" or "Extremely" bothered by the appearance of their MMP as measured by the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP) and attain a total score of ≥ 15 on the Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA), determined at the Day 1 visit.
Exclusion Criteria:
- Has current intraoral infection, including infection of the mouth or gums, or facial skin infection requiring medical treatment in the opinion of the investigator.
- Has weakness of the masseter, pterygoid, or temporalis muscles due to trauma, facial nerve injury, or other condition that could interfere with normal chewing and jaw clenching, as determined by the investigator.
- Excess lower facial fat, jowling, loose or lax skin in lower face, or parotid gland prominence that could interfere with MMPS or MMPS-P grading, as determined by the investigator.
- Has medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
- History of dental or surgical procedure for lower facial shaping or masseter muscle reduction.
- History of any soft tissue fillers in the jawline.
- Has prior exposure to botulinum toxin of any serotype to any part of the body (not including masseter muscle) within the 3 months prior to Day 1.
- History of or current TMJD, or presence of signs/symptoms of possible TMJD in the opinion of the investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Double-Blind Period: Botox
Participants will receive 6 intramuscular injections of BOTOX to the masseter on Day 1. |
Intramuscular Injections
Altri nomi:
|
|
Sperimentale: Open-Label Period: Botox
Participants who are eligible for retreatment will be given open-label BOTOX on Day 180 and will be followed for up to 6 months |
Intramuscular Injections
Altri nomi:
|
|
Comparatore placebo: Double Blind Period: Placebo
Participants will receive 6 intramuscular injections of Placebo to the masseter on Day 1. |
Intramuscular Injections |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale (MMPS) as assessed by the Investigator
Lasso di tempo: Day 90
|
The investigator assessed the severity of the participant's MMP using the MMPS 5-point scale where: 1=minimal (best), 2=mild, 3=moderate, 4=marked, and 5=very marked (worst). |
Day 90
|
|
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale - Participant (MMPS-P) as assessed by the Participant
Lasso di tempo: Day 90
|
The participant assessed the severity of their MMP using the MMPS-P 5-point scale where: 1=not at all pronounced (best), 2=mildly pronounced, 3=moderately pronounced, 4=pronounced, and 5=very pronounced (worst). |
Day 90
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Response of "Very Satisfied" or "Satisfied" on the Lower Facial Shape Questionnaire - Treatment Satisfaction Assessment (LFSQ-TXSAT)
Lasso di tempo: Day 90 to Day 180
|
The LFSQ-TXSAT measures the participant's satisfaction with the effect of treatment on the appearance of their lower face where 2=Very satisfied, 1=Satisfied, 0=Neither satisfied nor dissatisfied, -1=Dissatisfied, -2=Very dissatisfied. |
Day 90 to Day 180
|
|
Response of "Not at all bothered" or "A little bothered" on the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP)
Lasso di tempo: Day 90 to Day 180
|
The BIA-MMP is a single item evaluation of how bothered the participant is by the appearance of their lower face where 0=Not at all bothered, 1=A little bothered, 2=Somewhat bothered, 3=A lot bothered, 4=Extremely bothered. |
Day 90 to Day 180
|
|
Change from baseline in lower facial volume (cm^3)
Lasso di tempo: Day 90
|
Lower facial volume is calculated from standardized images |
Day 90
|
|
Change from baseline in lower facial width (mm)
Lasso di tempo: Day 90
|
Lower facial width is calculated from standardized images |
Day 90
|
|
Change from baseline in Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA) summary score
Lasso di tempo: Day 90 to Day 180
|
The LFSQ-IA is a 6-item assessment that measures psychosocial impact of the appearance of the lower face where 0= Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit and 4=Extremely. |
Day 90 to Day 180
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: ABBVIE INC., AbbVie
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- M23-123
- 2022-500568-37-00 (Altro identificatore: EU CT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Periodo di condivisione IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Criteri di accesso alla condivisione IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .